Download PDF
Semin Liver Dis 2016; 36(03): 291-296
DOI: 10.1055/s-0036-1584324
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Treatment of IgG4-Related Diseases in the Hepatobiliary-Pancreatic System

Terumi Kamisawa
1   Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
,
Sawako Kuruma
1   Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
,
Kazuro Chiba
1   Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
28 July 2016 (online)

    Permissions and Reprints

Abstract

An accurate diagnosis should be made before treatment of autoimmune pancreatitis and immunoglobulin G4-related sclerosing cholangitis. Once a diagnosis has been established, steroids are the standard therapy and symptoms are the major indications. Before steroid therapy, obstructive jaundice and hyperglycemia should be controlled. An initial dose of 0.6 mg/kg/d of oral prednisolone is administered for 2 to 4 weeks, and is gradually tapered over 2 to 3 months. After steroid therapy has begun, blood and imaging tests are performed periodically. Patients with a poor response to steroids should be reevaluated on suspicion of malignancy. To prevent relapse, maintenance therapy using low-dose prednisolone (2.5–5 mg/d) for 1 to 3 years is recommended in Japan. Proximal biliary stricture is reported to be a predictor of relapse. Readministration and dose-up of steroids are effective for relapses. In Western countries, immunosuppressive drugs and rituximab have also been shown to be effective. The optimal treatment regimen should be addressed in future randomized, controlled clinical trials.

Keywords

autoimmune pancreatitis - immunoglobulin G4 sclerosing cholangitis - steroid - rituximab - immunoglobulin G4-related sclerosing cholangitis
 

  • References

  • 1 Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015; 385 (9976) 1460-1471
    CrossrefPubMedGoogle Scholar
  • 2 Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M ; Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese Consensus Guidelines for Management of Autoimmune Pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45 (5) 471-477
    CrossrefPubMedGoogle Scholar
  • 3 Kamisawa T, Okazaki K, Kawa S , et al; Working Committee of the Japan Pancreas Society and the Research Committee for Intractable Pancreatic Disease supported by the Ministry of Health, Labour and Welfare of Japan. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014; 49 (6) 961-970
    CrossrefPubMedGoogle Scholar
  • 4 Kubota K, Iida H, Fujisawa T , et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 2007; 66 (6) 1142-1151
    CrossrefPubMedGoogle Scholar
  • 5 Kamisawa T, Anjiki H, Takuma K, Egawa N, Kubota N. The natural course of autoimmune pancreatitis. Hepatogastroenterology 2009; 56 (91–92) 866-870
    PubMedGoogle Scholar
  • 6 Hart PA, Kamisawa T, Brugge WR , et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62 (12) 1771-1776
    CrossrefPubMedGoogle Scholar
  • 7 Khosroshahi A, Wallace ZS, Crowe JL , et al; Second International Symposium on IgG4-Related Disease. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheum (Munch) 2015; 67 (7) 1688-1699
    CrossrefPubMedGoogle Scholar
  • 8 Kamisawa T, Egawa N, Inokuma S , et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas 2003; 27 (3) 235-238
    CrossrefPubMedGoogle Scholar
  • 9 Matsushita M, Yamashina M, Ikeura T , et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol 2007; 102 (1) 220-221
    PubMedGoogle Scholar
  • 10 Ghazale A, Chari ST, Zhang L , et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134 (3) 706-715
    CrossrefPubMedGoogle Scholar
  • 11 Sandanayake NS, Church NI, Chapman MH , et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7 (10) 1089-1096
    CrossrefPubMedGoogle Scholar
  • 12 Topazian M, Witzig TE, Smyrk TC , et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6 (3) 364-366
    CrossrefPubMedGoogle Scholar
  • 13 Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62 (6) 1755-1762
    CrossrefPubMedGoogle Scholar
  • 14 Kamisawa T, Shimosegawa T, Okazaki K , et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58 (11) 1504-1507
    CrossrefPubMedGoogle Scholar
  • 15 Park DH, Kim MH, Oh HB , et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology 2008; 134 (2) 440-446
    CrossrefPubMedGoogle Scholar
  • 16 Raina A, Yadav D, Krasinskas AM , et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104 (9) 2295-2306
    CrossrefPubMedGoogle Scholar
  • 17 Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Morphological changes after steroid therapy in autoimmune pancreatitis. Scand J Gastroenterol 2004; 39 (11) 1154-1158
    CrossrefPubMedGoogle Scholar
  • 18 Hart PA, Topazian MD, Witzig TE , et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62 (11) 1607-1615
    CrossrefPubMedGoogle Scholar
  • 19 Carruthers MN, Topazian MD, Khosroshahi A , et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74 (6) 1171-1177
    PubMedGoogle Scholar
  • 20 Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y. Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2011; 23 (2) 146-152
    CrossrefPubMedGoogle Scholar
  • 21 Uchida K, Yazumi S, Nishio A , et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol 2009; 44 (7) 726-732
    CrossrefPubMedGoogle Scholar
  • 22 Maruyama M, Arakura N, Ozaki Y , et al. Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients. Int J Rheumatol 2013; 2013: 272595
    PubMedGoogle Scholar
  • 23 Kamisawa T, Chari ST, Lerch MM, Kim MH, Gress TM, Shimosegawa T. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut 2013; 62 (9) 1373-1380
    CrossrefPubMedGoogle Scholar